Frank E. Stockdale
Academic Appointments
- Professor Emeritus, Medicine - Oncology
- Emeritus Faculty, Acad Council, Medicine - Oncology
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
Stanford Women�s Cancer Center 900 Blake Wilbur Stanford, CA 94305 Tel Work (650) 498-6004 Fax (650) 490-7237
- Academic Offices
Personal Information EmailAlternate Contact Diane Lee Administrative Assistant Email Tel Work 650-725-6449Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Breast Cancer
- Breast Cancer - Medical Oncology
- Oncology
- Newly Diagnosed Breast Cancer
- Metastatic Breast Cancer
- Inflammatory Breast Cancer
Honors and Awards
- Fellow, Guggenheim Foundation (1983)
- Fellow, AAAS (1999)
- AAP, American Association of Physicians (1976)
- ASCI, American Society for Clinic Investigation (1974)
- Elected, Best Doctors in America (2006-2013)
Professional Education
| Residency: | Stanford University School of Medicine CA (1967) |
| Medical Education: | University of Pennsylvania PA (1963) |
| Internship: | University Hospitals of Cleveland OH (1964) |
| Fellowship: | National Institutes of Health (1966) |
| A.B.: | Yale University, Zoology (1958) |
| Ph.D.: | University of Pennsylvania, Anatomy (1963) |
Internet Links
Scientific Focus
Current Research Interests
The focus of the research program are clinical trials in breast cancer. Clinical trials aim to investigate treatments for women with breast cancer who are newly diagnosed or have had a recurrence of breast cancer. Trials include participation in the national breast cancer study groups, ECOG and NSABP, as well as the development of new chemotherapy programs. Of particular interest are adjuvant therapy, treatment of metastatic disease, methods for treatment of locally advanced breast cancer and inflammatory breast cancer. Laboratory work has centered on the mechanisms of how cells acquire specific fates during growth and development , providing insights into normal and abnormal mechanisms of growth control.
Clinical Trials
- Not Recruiting Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
- Not Recruiting Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
- Not Recruiting A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
- Not Recruiting A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy
- Recruiting Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
Publications
- Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One. 2012; (5): e33788
- New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer. 2008: 66
- Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA. 2006; (20): 2374-84
- Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancer. Breast Cancer Res Treat. 2003; (1): 61-9
- Regulation of myosin expression during myotome formation. Development. 2003; (15): 3391-402
- Ventral axial organs regulate expression of myotomal Fgf-8 that influences rib development. Dev Biol. 2003; (1): 30-47
Help